1
|
Torre-Gutiérrez LGDL, Martínez-Zérega BE, Oseguera-Galindo DO, Aguilar-Lemarroy A, Jave-Suárez LF, Torres-González LA, González-Solís JL. Breast cancer chemotherapy treatment monitoring based on serum sample Raman spectroscopy. Lasers Med Sci 2022; 37:3649-3659. [PMID: 36239879 PMCID: PMC9562073 DOI: 10.1007/s10103-022-03646-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2022] [Accepted: 09/18/2022] [Indexed: 11/30/2022]
Abstract
In this paper, breast cancer patients were monitored throughout their chemotherapy treatments (CHT), with blood serum sample Raman spectroscopy and multivariate analysis, approximately for a year. First of all, we discriminate between healthy and clinically diagnosed breast cancer patients. Breast cancer detection in terms of sensitivity and specificity were 87.14% and 90.55% respectively. Although no shifts of peaks in mean spectrum of samples from breast cancer patients were found with respect to the mean spectrum from control patients, some peaks did show clear differences in intensity, the greatest disparities found at 509, 545, 1063, 1103, 1338, 1556, 1083 and 1449 cm− 1 are associated with amino acids and phospholipid, 1246 and 1654 cm− 1, corresponding to amide III and I, respectively. Other peaks of interest encountered at 450, 661, 890, 917 and 1405 cm− 1 are associated to glutathione. Then, 6 breast cancer patients were monitored during their chemotherapy treatments, the results were in complete correspondence with their medical records, enabling a detailed study of the evolution of each patient’s cancer. A special interest arose in the possible correlation between the intensity of Raman peak, 450 cm− 1, corresponding to glutathione and evolution of cancer throughout CHT, i.e., glutathione appears to be a good candidate as breast cancer biomarker. The results confirmed that Raman spectroscopy and PCA are, not only a good support to current breast cancer detection techniques, but could also be excellent techniques to monitor more efficiently breast cancer patients undergoing CHT, using blood serum samples which are a lot less invasive than other methods.
Collapse
Affiliation(s)
- L G De la Torre-Gutiérrez
- Biophysics and Biomedical Sciences Laboratory, Centro Universitario de los Lagos, Universidad de Guadalajara, Enrique Díaz de León 1144, Paseo de la Montaña, Lagos de Moreno, 47460, Jalisco, México
| | - B E Martínez-Zérega
- Biophysics and Biomedical Sciences Laboratory, Centro Universitario de los Lagos, Universidad de Guadalajara, Enrique Díaz de León 1144, Paseo de la Montaña, Lagos de Moreno, 47460, Jalisco, México.
| | - D O Oseguera-Galindo
- Departamento. Cs. Naturales y Exactas, Centro Universitario de los Valles, Universidad de Guadalajara, Carretera Guadalajara - Ameca Km. 45.5, Ameca, 46600, Jalisco, México
| | - A Aguilar-Lemarroy
- Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Sierra Mojada 800, Col. Independencia, Guadalajara, 44340, Jalisco, México
| | - L F Jave-Suárez
- Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Sierra Mojada 800, Col. Independencia, Guadalajara, 44340, Jalisco, México
| | - L A Torres-González
- Departamento de Ingeniería, Universidad Iberoamericana León, Blvd. Jorge Vértiz Campero, Fracciones Canadá de Alfaro, León, 37238, Guanajuato, México
| | - J L González-Solís
- Biophysics and Biomedical Sciences Laboratory, Centro Universitario de los Lagos, Universidad de Guadalajara, Enrique Díaz de León 1144, Paseo de la Montaña, Lagos de Moreno, 47460, Jalisco, México
| |
Collapse
|